Health care professionals at risk of infection with Borna disease virus – evidence from a large hospital in China (Chongqing) by Xia Liu et al.
Liu et al. Virology Journal  (2015) 12:39 
DOI 10.1186/s12985-015-0239-yRESEARCH Open AccessHealth care professionals at risk of infection with
Borna disease virus – evidence from a large
hospital in China (Chongqing)
Xia Liu1,2†, Liv Bode3†, Liang Zhang1,3,4†, Xiao Wang3,4†, Siwen Liu3,4, Lujun Zhang3,4, Rongzhong Huang5,
Mingju Wang1,3,4, Liu Yang3,4, Shigang Chen3,4, Qi Li1, Dan Zhu1, Hanns Ludwig3 and Peng Xie1,3,4*Abstract
Background: Human Borna disease virus (BDV) infections have recently been reported in China. BDV causes
cognitive and behavioural disturbances in animals. The impact on human mental disorders is subject to debate, but
previous studies worldwide have found neuropsychiatric patients more frequently infected than healthy controls. A
few isolates were recovered from severely depressed patients, but contagiousness of BDV strain remains unknown.
Method: We addressed the risk of infection in health care settings at the first affiliated hospital of Chongqing
Medical University (CQMU), located in downtown Chongqing, a megacity in Southwest China. Between February
2012 and March 2013, we enrolled 1529 participants, of whom 534 were outpatients with major depressive disorder
(MDD), 615 were hospital personnel, and 380 were healthy controls who underwent a health check. Infection was
determined through BDV-specific circulating immune complexes (CIC), RNA, and selective antibodies (blood).
Results: One-fifth of the hospital staff (21.8%) were found to be infected (CIC positive), with the highest prevalence
among psychiatry and oncology personnel, which is twice as many as were detected in the healthy control group
(11.1%), and exceeds the prevalence detected in MDD patients (18.2%).
Conclusion: BDV circulates unnoticed in hospital settings in China, putting medical staff at risk and warranting
clarification of infection modes and introduction of prevention measures.
Keyword: Borna disease virus, Risk of infection at hospital, Health care professionals, Major depressive disorder,
Circulating immune complexes, RT-qPCR, ChinaBackground
Major depressive disorder (MDD) is a debilitating psychi-
atric illness with a wide variation in lifetime prevalence
across countries. Mean estimates are 14.6% in high- and
11.1% in low-middle income countries according to the
World Mental Health Survey, with China (Shenzen) ran-
ging among countries with the lowest lifetime estimates
(6.5%) [1]. On a global scale, among mental and substance
use disorders which account for one-fifth (22.9%) of all* Correspondence: xiepeng@cqmu.edu.cn
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contributed the most, accounting for 42.2% of years lived
with disability (YLDs) [1]. The hypothesis that an ancient
neurotropic virus, Borna disease virus (BDV), may con-
tribute to MDD’s multi-factorial etiology has been sup-
ported by numerous studies demonstrating serological
and molecular epidemiological evidence not only for hu-
man infection but for differences between psychiatric pa-
tients and healthy controls [2].
BDV (Bornaviridae; Mononegavirales), a non-cytolytic
RNA virus, preferentially infects limbic structures and
causes cognitive deficiencies and behavioral abnormal-
ities in rodents [3]. Remarkably, human BDV strain Hu-
H1, isolated from a severely depressed bipolar patient’s
blood cells in Germany [4], promotes apoptosis and in-
hibits cell proliferation in vitro, whereas laboratory strains is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1927) and having a history of multiple passaging (rabbits,
rats, cell culture), does the opposite [5]. MDD patients
display higher detection rates of BDV-specific RNA
transcripts in lymphocytes, increased serum antibody ti-
ters against BDV-specific nucleoprotein (p40) and
phosphoprotein (p24), and higher prevalence of BDV-
specific circulating immune complexes (CIC) than
healthy individuals [6-10]. The predominance of CIC to
indicate active infection has recently been confirmed in
2014 by Mazaheri-Tehrani et al. who investigated clinic-
ally accurately diagnosed psychiatric patients and did
detect a high infection (CIC) prevalence of 40.4% which
was significantly different from that of healthy controls
(29.5%; p = 0.036) [11]. However, using methods deter-
mining BDV-specific antibodies or nucleic acids, a re-
cent study failed in respect of either psychiatric patients
or control subjects [12]. Differing sensitivities in detection
methods currecnly impair comparability of worldwide
prevalence data. Among all markers/methods currently in
use, BDV-CICs, not only are the most frequent indicators
of virus infection, but also reasonably explain infection
profiles of dormant and activated states, the latter charac-
terized by antigen production, release into the plasma,
host antibody response, and formation of CIC [2,7].
Regardless of flaws due to methods-driven discrepancies,
the BDV hypothesis stays intriguing because it is fitting as
well in other models like the concept of stress-induced de-
pression [13], as hypothalamic-pituitary-adrenal (HPA) sys-
tem activity in depressed patients has been associated with
BDV but not with other infections [14].
The transmission mode of BDV is still elusive, but
nasal, conjunctiva secretions, saliva and blood are likely
sources [15]. In family members and mental healthcare
workers of psychiatric patients, higher BDV infection
prevalence has been reported in comparison with unre-
lated persons [16]. Whether hospital personnel are at
risk of acquiring BDV infection through patients’ care is
public health issue of considerable relevance, particularly
in densely populated countries such as China, where
BDV research is still scarce [17].
Here, we report a cross-sectional epidemiological survey
of BDV infection including MDD outpatients, hospital
personnel and healthy individuals who underwent a
health check-up at the 3000-beds First Affiliated Hospital
of Chongqing Medical University (CQMU) in Chongqing,




All subjects gave their written informed consent after a
detailed introduction to the study. Either of the parents
of the minors gave their written informed consent onbehalf of their participating child. Among the MDD pa-
tients 17 adolescents aged 15–17 years were included.
The study was approved by the Ethics Committee of
Chongqing Medical University (#2011002) and was per-
formed according to the Helsinki Declaration.
Study population
A total of 1529 participants were recruited at the above-
mentioned hospital between February 2012 and March
2013, and assigned to the three groups described
(Table 1).
MDD outpatients were enrolled at the Psychiatric Center
and ranked for severity according to DSM-IV criteria and
the 17-item version of the Hamilton Depression Rating
Scale (HDRS). A total of 534 MDD outpatients were in-
cluded (males = 187, females = 347) aged 15 to 66 years
(mean = 35.99 ± 12.23 years, median = 36 years). Patients
with confounding factors, such as pre-existing physical or
mental disorders other than MDD, medication, and/or
illicit drug use, were excluded. A total of 615 hospital
personnel members (males = 182, females = 433) aged 20
to 81 years (mean = 39.28 ± 11.61 years, median = 39 years)
were included after accepting HDRS assessment. At the
same time, 380 healthy controls (males = 160, females =
220) aged 21 to 64 years (mean = 35.58 ± 10.86 years, me-
dian = 33.50 years) were recruited from the Medical Exam-
ination Center. Candidates with any lifetime history of
neurological, DSM-IV Axis I or II, and/or systemic illness
were excluded.
Plasma and peripheral blood mononuclear cell (PBMC)
preparations
EDTA-treated blood samples (10 ml) were separated
into PBMCs and plasma by Ficoll-Conray centrifugation
(density, 1.087 g/ml) and stored at −80°C.
CIC assays
Plasma-based BDV CIC was assayed as previously de-
scribed and standardized [7]. Test specificity is based on
two monoclonal antibodies (mAbs), BDV p40 (W1) and
p24 (Kfu2) [18], binding to conformational epitopes on ei-
ther N or phosphorylated P-protein including N/P hetero-
dimers according to epitope mapping [19]. Sensitivity has
been determined for W1 mAb using purified recombinant
N-protein (limit 0.15-0.3 ng/100 μl/well) [19]. In brief, poly-
styrene 96-well plates (MaxiSorp; Nunc) were coated with
anti-mouse IgG Fc (1:1000 for 1 h at 37°C, Jackson Immu-
noResearch). After washing, BDV mAbs (hybridoma super-
natant, 1:500 each for 1 h at 37°C) were added. Estimated
total mAb concentration per well (0.2 μg) was equivalent
to that of anti-mouse IgG, but exceeding 1000 times the
detection limit for N-protein. This step included block
proteins (fetal calf serum) in 200-fold excess. After wash-
ing, plasma samples (1:20 and serially two-fold dilution in








Group I vs. II Group I vs. III Group II vs. III All three groups
Sample size 534 615 380
Age (year)a, b 35.99 ± 12.23 39.28 ± 11.61 35.58 ± 10.86 0.000 0.885 0.000 0.000e
<25 116 38 57
25-39 217 284 193
40-54 147 226 105
55-70 54 56 25
>70 0 11 0
Sex (M/F)c 187/347 182/433 160/220 0.049 0.030 0.000
HDRS scorea,d 20.58 ± 7.00 2.2 ± 0.8 1.2 ± 1.0 0.000 0.000 0.143
CIC+ (%)c 97 (18.2%) 134 (21.8%) 42 (11.1%) 0.001 0.024 0.000
p24 RNA+ (%)c 27 (5.1%), 50 (8.1%), 8 (2.1%), 0.038 0.022 0.000
CIC+ and p24 RNA +c 21 (3.9%), 48 (7.8%) 5 (1.3%) 0.006 0.019 0.000
CIC+ and/or p24 RNA +c 103 (19.3%), 136 (22.1%), 45 (11.8%), 0.239 0.003 0.000
CIC- and p24 RNA+ 6 2 3
CIC level 0.197f
Negative and borderline 437 454 332
Weakly/1+ positive 82 134 42
2+ positive 14 23 6
3+ and 4+ positive 1 4 0
Antibody+/CIC+ 5/50 3/50 4/40
Antibody+/CIC+ 0/50 1/50 1/40
Abbreviations: MDD major depressive disorder, M male, F female, HDRS Hamilton Depression Rating Scale, CIC circulating immune complexes, p24 BDV
phosphoprotein 24, RNA ribonucleic acid. aValues expressed as means ± SDs.,bMann-Whitney test,cChi-square test,dOne-way ANOVA,eKruskal-Wallis
test,fSpearman correlation.
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from a German MDD patient (CIC, optical density (OD) =
0.486 at 415 nm) and a healthy German individual (OD=
0.09) were used throughout all experiments as positive and
negative controls, respectively. After washing, alkaline
phosphatase-conjugated anti-human IgG (1:3000 in TBS-T,
Jackson ImmunoResearch) was applied for 1 h at 37°C.
After washing, freshly prepared substrate p-nitrophenyl-
phosphate (pNPP, 1 mg/ml) in 1 M diethanolamine buffer
(AP Substrate Kit, Bio-Rad) was added (5 min at room
temperature, visual control), followed by a stop using 50 μl
of 3 M sodium hydroxide. A Bio-Rad imarkMicroplate
Reader was used at 415 nm. The OD levels of BDV CIC
were scored as previously described [7]:
negative, cut-off value (OD ≤ 0.10); borderline
(OD > 0.10 – 0.12);
weakly positive (OD >0.12 – 0.15); >
1+ positive (OD >0.15 – 0.30);
2+ positive (OD >0.30 – 0.6);
3+ positive (OD >0.60 – 1.00); and
4+ positive (OD >1.00).Plasma samples determined to be positive by the initial
EIA were tested a second time. All positive samples from
the three groups (306/1529) were evenly distributed to
each plate in the second round. Those samples that
tested positive in both rounds (273/1529) were deemed
positive.
Antibody assays
BDV antibodies in blood plasma were determined as
previously described [7], with slight modifications as fol-
lows: the first two steps as CIC assay including coating
with Goat Anti-Mouse IgG and then with BDV p40 and
p24 mouse monoclonal antibodies. After washing, ultra-
sonicated BDV strain Hu-H1 infected oligodendroglia
(OL) cells (titer 1.1 × 104 focus forming units ml −1), di-
luted 1:50 in PBS-T, were incubated 1 h at 37°C. After
washing, plasma samples, diluted 1:100 and serially two-
fold in PBS-T, were incubated for 2 h at 37°C. The next
steps were the same as for the CIC assay.
Due to limited volumes, only 280 plasma samples were
additionally examined by the BDV antibody assay. Samples
were randomly selected as follows: 50 plasma samples
Table 2 Gender or Age and CIC prevalence in all three
groups
CIC- CIC+ Totals CIC+ %
Gender
Male 442 87 529 16.4%
Female 814 186 1000 18.6%
Totals 1256 273 1529 17.9%
Age group
<25 173 38 211 18.0%
25-39 566 128 694 18.4%
40-54 375 103 478 21.5%
55-70 102 33 135 24.4%
>70 7 4 11 36.4%
Totals 1223 306 1529 20.0%
Prevalence in females compared to males was higher but not significant
(Chi-Square tests: χ2 = 1.094, p = 0.296) CIC prevalence increases with age
(Chi-Square tests: χlinear2 = 4.682, p = 0.030).
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tive and CIC negative results, as well as 40 samples each
from healthy controls with CIC positive and CIC negative
results.
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA was extracted from PBMCs using Trizol (Life
Technologies) according to the manufacturer’s proto-
cols, dissolved in 25 μl of DNase/RNase-free H2O, and
stored at −80°C. RNAs from uninfected oligodendrocytes
(negative control) and RNAs from BDV-infected oligo-
dendrocytes (positive control) were simultaneously proc-
essed. RNA was reverse-transcribed into cDNA (Reverse
Transcriptase System, Promega), then incubated with
random primer and 30 units of reverse transcriptase for
60 min at 42°C. After enzyme inactivation (5 min at
95°C), the cDNA was stored at −20°C.
RT-qPCR was performed as previously described [20].
In brief, PCR amplification was performed in 25 μl per
well, each containing 12.5 μl of 2 × TaqMan Universal
PCR Master Mix with UNG (Applied Biosystems), 600
nM p24 primer, 160 nM p24 probe, and 3.5 μl of cDNA.
The PCR steps were as follows: 2 min at 50°C to activate
the uracil-N-glycosylase (UNG) that detects and de-
grades the former PCR products; 10 min at 95°C to in-
activate UNG and activate the polymerase; 40 cycles of
denaturation at 95°C for 15 s; annealing and elongation
at 60°C for 1 min. All reactions were run in a Corbett
Research Rotor-Gene 6000 thermocycler including a no-
template control (sterile water) and repeated at least
three times. Signals were regarded as positive only if the
fluorescence intensity exceeded 10 times the standard
deviation of the baseline fluorescence (threshold). Cq values
greater than 40 were regarded as negative. Eukaryotic 18S
rRNA (Applied Biosystems) was amplified as an endogen-
ous control.
Cloning and sequencing of RT-qPCR products
RT-qPCR products were cloned into the pGEM-T Easy
vector system (Promega). One to three clones of each
product were sequenced by the Applied Biosystems
Prism dye-terminator dideoxy system at a commercial
facility (BGI Life Tech. Beijing, China). Sequences were
analyzed by comparison with GenBank.
Results
BDV-specific CIC
Of the 1529 individual samples analyzed by BDV-
specific CIC EIA, 273 were positive (17.9%; 18.6% fe-
males (186/1000) and 16.4% males (87/529)). While CIC
prevalence among the three groups was significantly
different, CIC levels were not (p = 0.197, Spearman cor-
relation; Table 1). Gender differences were not signifi-
cant either (p = 0.296, Chi-Square test), in contrast toage (p = 0.030, Chi-Square Test) (Table 2). The trend of
CIC prevalence increasing with age remained after ad-
justment to ages present in all three groups (Table 1).
BDV-specific CICs were differentially detected in
18.2% (97/534) of MDD outpatients vs. 11.1% (42/380)
of healthy controls (p = 0.024, Chi-Square test). The se-
verity of depression, however, was neither related to CIC
prevalence (p = 0.194, Chi-Square test) nor CIC levels
(p = 0.600, Spearman’s correlation; Table 3). MDD outpa-
tients and healthy controls were matched to age but
not gender (age, p = 0.885, Mann–Whitney test; gender,
p = 0.030, Chi-Square test; Table 1).
BDV-specific CICs were significantly more prevalent in
hospital personnel (134/615) than in MDD outpatients
(21.8% vs. 18.2%; p = 0.001, Chi-Square test) and healthy
controls (21.8% vs. 11.1%, p = 0.000, Chi-Square test).
Overall, no significant association between CIC prevalence
and type of hospital department was found (p = 0.941,
Chi-Square test), but a trend to slightly higher CIC preva-
lence was obseved among oncology and psychiatry
personnel (p = 0.540, Chi-Square test) (Table 4).
BDV-specific antibodies
Of randomly selected MDD patients who had tested
CIC-positive, 10% had antibodies (5/50), as opposed to
none of CIC-negative patients (0/50). Of the hospital
personnel, 6% (3/50) of the CIC-positive and 2% (1/50)
of the CIC-negative tested positive for antibodies. In the
healthy control group, 10% (4/40) of the CIC-positive
and 2.5% (1/40) of the CIC-negative subjects tested posi-
tive for antibodies,
BDV p24 RNA in PBMCs
Negative and positive controls performed appropriately
in each RT-qPCR assay, with Cq values of BDV+ control
Table 3 CIC prevalence or CIC levels and HDRS in MDD
outpatients
HDRS score
0-7 8-16 17-23 ≥24 Totals
CIC prevalence
CIC- 26 53 218 140 437
CIC+ 10 11 39 37 97
Totals 36 64 257 177 534
CIC+ % 27.8% 17.2% 15.2% 20.9% 18.2%
CIC level
Negative and borderline 26 53 218 140 437
Weakly positive 3 5 11 7 26
1+ positive 6 6 21 23 56
2+ positive 1 0 6 7 14
3+ positive 0 0 1 0 1
Totals 36 64 257 177 534
BDV prevalence was not significantly related to the severity of depression
(Chi-Square tests: χ2 = 4.718, p = 0.194). CIC levels were not significantly related
to the severity of depression (Spearman’s correlation coefficient =0.023, p =0.600).
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was appropriate due to Cq values of 18S RNA which
were between 20 and 25 cycles as well. Specificity of
amplification products was demonstrated by DNA se-
quencing revealing a greater than 96% identity with
GenBank’s BDV p24 fragments.
BDV p24 RNA was present in PBMCs from 5.1% of
MDD outpatients (27/534), 8.1% of hospital personnel
(50/615), and 2.1% of healthy controls (8/380). RNA+ in-
dividuals were not always CIC+. The differences across
all groups were significant (Table 1).
Discussion
This is the largest survey ever performed on human
BDV infection, representatively conducted in a hospital
setting of a Chinese megacity with high urban density
(Chongqing). The survey involved more than 1500 sub-
jects including comparable numbers of MDD patients,Table 4 CIC prevalence by hospital department
Department CIC- CIC+ Totals CIC+ %
Oncology and psychiatry 15 7 22 31.8%
General/Internal medicine 253 87 340 25.6%
Medical laboratory 60 23 83 27.7%
Administrative staff logistics 94 36 130 27.7%
Not recorded 32 8 40 20.0%
Totals 454 161 615 26.2%
No correlation between BDV infection and department distribution was found
(Chi-Square tests: χ2 = 0.395, p = 0.941). A trend to a somewhat higher CIC
prevalence at oncology and psychiatry compared to other departments
(Chi-Square test, p = 0.540).hospital staff, and controls. The study used two sero-
logical methods and one molecular biological method,
determining BDV- CIC and antibodies (selected panel)
in plasma and BDV-p24-RNA in PBMCs.
We applied the specificity-proven BDV CIC EIA here
[19] to screen for the most prevalent plasma-based indi-
cator of BDV infection [7]. As explained, CIC monitor-
ing allows comparative prevalence analysis of infected
subjects who undergo periods of virus activity accom-
panied by over-expression and shedding of BDV proteins
(N/P) into the plasma which, in turn, leads to antibody
generation and subsequent CIC formation [2,19]. Com-
pared to CIC, the mean antibody prevalence in the
Chinese healthy controls was significantly lower (5/80;
6.25%), although a selection bias of 50% CIC-positive
samples was used. Our study supported previous find-
ings [2] that through CIC formation antibodies become
less frequent in the plasma and are inferior to CIC for
estimating the prevalence of BDV infection. Based on
CIC, BDV infection in healthy individuals is considerably
less prevalent in Southwest China (11.1%) in comparison
to European countries such as Germany (32.3%) [2,7]
and the Czech Republic (37.3%) [21], or to Middle East
countries like Iran (29.5%) [11], suggesting large regional
differences. We also confirm previously described sig-
nificant differences in CIC prevalence between MDD
outpatients and healthy controls [2], thereby providing
further evidence that BDV infection may play a role in
MDD pathogenesis. This implies at the same time that
infected healthy people are at risk, and increased CIC
prevalence would indicate frequent activation.
The novelty of our approach is to address the risk of
infection for medical staff in professional health care set-
tings, where MDD patients, hospital workers in charge
of patients’ care, and healthy controls undergoing health
check-up were all present at the same hospital in a lim-
ited time period of 12–13 months.
What we found was a considerably higher exposure of
hospital personnel to BDV infection compared to unre-
lated healthy people, in line with a smaller previous re-
port [16]. In our study, the CIC prevalence of medical
staff (21.8%) was similar to that of MDD patients
(18.2%), and double that of healthy controls without
contact with MDD patients (11.1%). Here, one-third of
the psychiatry and oncology department personnel (the
departments with the highest CIC prevalence) were
found to be infected, even though inter-department dif-
ferences were not significant. Patients in these depart-
ments may shed virus more frequently due to elevated
virus activation. Immune-competent hospital staff may
be able to cope with an elevated exposure to infections
as well as high stress levels which in turn promote BDV ac-
tivation [14]. Then again, sub-clinically infected personnel
are a potential source of keeping BDV circulating in hospitals.
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hospital personnel are exposed to their elevated health risks.
Our study confirms that plasma-based CICs were not
only superior to antibody detection but also to PBMC-
based BDV p24 RNA for monitoring BDV infection. The
majority of subjects were CIC positive with no detectable
PBMC-based BDV RNA, indicating antigen release into
the plasma (antigenaemia) and CIC formation after pri-
mary viremia, consistent with the often discordant pres-
ence of serological and RNA markers [6,7]. This disparity
is due to over-expressed viral proteins (N/P) vs. a low rep-
lication rate of viral RNA [22], which also explains why
the highly sensitive RT-qPCR method is less effective in
BDV infection monitoring than antigen-driven CIC [2].
Based on more than 1500 subjects in a hospital setting
of a Chinese megacity, we found a considerable BDV in-
fection risk among hospital personnel and an association
between BDV infection and Chinese MDD patients. Com-
pared to Europe and the Middle-East [2,7,11,21], our study
revealed a lower prevalence of BDV infection in healthy
people in Chongqing (Southwest China), which increased
as a function of age. Unknown transmission of BDV dur-
ing health care activities which put medical personnel at
risk are alarming findings that warrant further serious at-
tention through infection monitoring and preventive mea-
sures in China and elsewhere. Our study may alert BDV
researchers to conduct further epidemiological surveys,
identify transmission routes, and further clarify how BDV
infection is linked to psychiatric disorders.
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